ALTMAN, MICHAEL D.,阿特曼 麦克 Ｄ,阿特曼 麥克 Ｄ,CASH, BRANDON D.,凯许 布兰登 Ｄ,凱許 布蘭登 Ｄ,CHILDERS, MATTHEW LLOYD,乔得思 马修 洛伊德,喬得思 馬修 洛伊德,CUMMING, JARED N.,卡门 杰瑞 Ｎ,卡門 傑瑞 Ｎ,DEMONG, DUANE E.,迪蒙 杜恩 Ｅ,HAIDLE, ANDREW
申请号：
TW108111487
公开号：
TW202003509A
申请日:
2019.04.01
申请国别(地区):
TW
年份:
2020
代理人:
摘要：
Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.本發明提供通式(I)、通式(II)、通式(III)、通式(IV)、通式(V)、通式(VI)之化合物及其醫藥上可接受之鹽，其中所有變數定義於本文中，其可用作I型干擾素產生之誘導劑，特定用作STING活性劑。本發明亦提供包含此等化合物之組合物、用於合成此等化合物之製程，及此等化合物之用途，包括投與此等化合物以誘導免疫反應、誘導STING依賴性I型干擾素產生，及/或治療細胞增殖病症，諸如癌症。
